Compare Inovio Pharmaceuticals Inc (INO) vs SP Funds S&P 500 Sharia Industry Exclusions ETF (SPUS) Price & Performance

INO trades at $1.10, down 1.79% recently, with a bearish technical signal from moving averages. The company shows minimal revenue of $65,340 in 2025 and a net loss of $84.95 million, resulting in negative profitability margins. Recent news highlights an ongoing FDA review for INO-3107 with a PDUFA date of October 30, 2026, while shareholder litigation investigations emerge. Cash flow remains negative, though operating expenses have declined.

The investment case hinges on the binary FDA decision for INO-3107, offering potential upside if approved, but carries high risk due to persistent losses, negative cash flow, and legal scrutiny. Analyst consensus is moderately bullish with 53% buy ratings, but fundamental weaknesses and technical bearishness suggest cautious positioning is warranted.

SPUS trades at $56.32, down 0.23% on the day, with a bearish technical outlook from moving averages and oscillators. Key support is at $56, with resistance at $57. The stock's financial ratios, including P/E and P/S, are not available in the provided data. Recent corporate actions include small dividend payments scheduled for mid-2026, indicating a shareholder return focus.

The outlook for SPUS is cautious due to weak technical signals and limited fundamental data visibility. Investment opportunities may lie in its dividend strategy, but risks include market volatility and lack of current financial metrics. Investors should seek updated earnings reports for a clearer fundamental picture before considering a position.